Sulforaphane rescues memory dysfunction and synaptic and mitochondrial alterations induced by brain iron accumulation. (20th August 2015)

• Record Type: Journal Article
• Authors: Lavich, I.C.; de Freitas, B.S.; Kist, L.W.; Falavigna, L.; Dargél, V.A.; Köbe, L.M.; Aguzzoli, C.; Piffero, B.; Florian, P.Z.; Bogo, M.R.; de Lima, M.N.M.; Schröder, N.
• Is Part Of: Neuroscience. Volume 301(2015)
• Page Start: 542
• Page End: 552
• Publication Date: 2015-08-20
• Subjects: AD Alzheimer's disease -- ANOVA analysis of variance -- EDTA ethylenediaminetetraacetic acid -- HD Huntington's disease -- HDAC histone deacetylase -- OPA1 optic atrophy type 1 -- PD Parkinson's disease -- ROS reactive oxygen species; sulforaphane -- iron -- mitochondria -- recognition memory -- synapse -- neurodegenerative disorders; Neurochemistry -- Periodicals; Neurophysiology -- Periodicals; Neurology -- Periodicals; Neurochimie -- Périodiques; Neurophysiologie -- Périodiques; Neurochemistry; Neurophysiology; Electronic journals; Periodicals; Electronic journals; 612.8
• DOI: 10.1016/j.neuroscience.2015.06.025
• Languages: English
• ISSNs: 0306-4522

Abstract

Highlights: Sulforaphane reverses memory impairments associated with brain iron accumulation. Sulforaphane recovers mitochondrial fission protein DNM1L decrease induced by iron. Sulforaphane recovers iron-induced reduction in the synaptic marker synaptophysin. Sulforaphane may be considered for the treatment of cognitive deficits. Abstract: Iron overload contributes to the development of neurodegeneration and the exacerbation of normal apoptosis rates, largely due to its participation in the Fenton reaction and production of reactive oxygen species (ROS). Mitochondria constitute the major intracellular source of ROS and the main target of attack by free radicals. They are dynamic organelles that bind (fusion) and divide (fission) in response to environmental stimuli, developmental status, and energy needs of the cells. Sulforaphane (SFN) is a natural compound that displays antioxidant and anti-inflammatory activities. This study aims to investigate the effects of SFN on memory deficits and changes in markers of mitochondrial function, DNM1L and OPA1, and the synaptic marker, synaptophysin, induced by neonatal iron treatment. Male rats received vehicle or carbonyl iron (30 mg/kg) from the 12th to the 14th postnatal day. In adulthood, they were treated with saline or SFN (0.5 or 5 mg/kg) for 14 days every other day. Memory deficits were assessed using the object recognition task. DNM1L, OPA1, and synaptophysin levels in the hippocampus were quantified by Western blotting. Results showed that SFN was able to reverse iron-induced decreases in mitochondrial fission protein, DNM1L, as well as synaptophysin levels in the hippocampus, leading to a recovery of recognition memory impairment induced by iron. These findings suggest that SFN may be further investigated as potential agent for the treatment of cognitive deficits associated with neurodegenerative disorders.